newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//The Hindu Business Line
UK pharmaceutical group GSK is in talks to buy cancer drugmaker Nuvalent for more than $9 billion, the Financial Times reported.
GSK is in advanced talks to acquire Nuvalent for over $9 billion.
KEY POINTS
The potential acquisition deal could be finalized as soon as this week.
Nuvalent's current market value is about $7 billion, notably less than the proposed offer.
This acquisition would contribute to a record surge in biopharma M&A deals projected in 2026.
UK pharmaceutical group GSK is in talks to buy cancer drugmaker Nuvalent for more than $9 billion, the Financial Times reported on Monday, citing people familiar with the matter.
Here are some details:
* The companies were locked in discussions late on Monday, aiming to agree on a deal as soon as this week, the report said.
* A potential deal could value Nuvalent between $9 billion and $10 billion, according to the report.
* Reuters could not immediately verify the report. Nuvalent and GSK did not immediately respond to Reuters requests for comment.
* Nuvalent has a market value of nearly $7 billion, according to LSEG data.
* Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, according to its website.
* The deal comes at a time of biotech dealmaking frenzy, with large drugmakers on a spending spree to expand their product pipelines this year. If the current pace holds, the total biopharma M&A value could exceed $250 billion in 2026, according to a Stifel note in April.
Published on June 9, 2026